Increased disease activity in eNOS-deficient mice in experimental colitis

Oral dextran sodium sulfate (DSS, 3%) produces experimental colitis with many features of human inflammatory bowel disease (IBD), (leukocyte extravasation, cachexia, and histopathology). Previous studies suggest that the inducible nitric oxide synthase (iNOS) in blood cells or in the endothelium con...

Full description

Saved in:
Bibliographic Details
Published inFree radical biology & medicine Vol. 35; no. 12; pp. 1679 - 1687
Main Authors Sasaki, M, Bharwani, S, Jordan, P, Elrod, J.W, Grisham, M.B, Jackson, T.H, Lefer, D.J, Alexander, J.Steven
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.12.2003
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oral dextran sodium sulfate (DSS, 3%) produces experimental colitis with many features of human inflammatory bowel disease (IBD), (leukocyte extravasation, cachexia, and histopathology). Previous studies suggest that the inducible nitric oxide synthase (iNOS) in blood cells or in the endothelium contribute to this injury. However, until now no study has been performed to directly evaluate the role of endothelial nitric oxide synthase (eNOS) in IBD. We compared disease activity in wild-type (eNOS +/+) and eNOS-deficient (eNOS −/−) mice in the DSS model of colitis. Administration of DSS induced weight loss, stool blood, and overt histopathology in both mouse strains. Disease activity was dramatically increased in eNOS −/− mice compared to wild types. Histologically, eNOS-deficient mice had greater leukocyte infiltration, gut injury, and expressed higher levels of the mucosal addressin, MAdCAM-1. These results demonstrate that eNOS plays an important role in limiting injury to the intestine during experimental colitis and altered eNOS content and/or activity may contribute to human IBD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0891-5849
1873-4596
DOI:10.1016/j.freeradbiomed.2003.09.016